TMS Social Consensus Review and Treatment for TMS Therapy

Clinical TMS Society Consensus Review and Treatment for TMS Therapy PDF

By: Tarique Perera, Mark S. George, Geoffrey Grammer, Philip G. Janicak, Alvaro Pascual-Leone, Theodore S. Wirecki,

Background: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4–6 weeks (20–30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Green- wich, CT, USA), incorporated in 2013.

Methods: This consensus review was written by TMS leaders, informed by members hippos,and approved by the governing board. It summarizes current evidence for the safety and efficacy of the use of TMS therapy for treating depression in routine clinical practice. Authors systematically reviewed the published TMS antidepressant therapy clinical trials. Studies were then assessed and graded on their strength of evidence using the Levels of Evidence framework published by the University of Oxford Centre for Evidence Based Medicine. The authors then summarize essentials for using the therapy in routine clin- ical practice settings derived from discussions and polls of TMS members. Finally, each summary clinical recommendation is presented with the substantiating peer-reviewed, published evidence supporting that recommendation. When the current published clinical trial evidence was insufficient or incomplete, expert opinion was included when sufficient consensus was available from experienced clinician users among the membership of the cTMSs, who were polled at the Annual Meetings in 2014 and 2015.  Conclusions: Daily left prefrontal TMS has substantial evidence of efficacy and safety for treating the acute phase of depression in patients who are treatment resistant or intolerant. Following the clinical recommendations in this document should result in continued safe and effective use of this exciting new treatment modality.

TMS therapy uses a computerized, electromechanical medical device to produce and deliver non-invasive, magnetic stimulation using brief duration, rapidly alternating, or pulsed, magnetic fields to induce electrical currents directed at spatially discrete regions of the cerebral cortex. This method of cortical stimulation by application of brief magnetic pulses to the head is known as transcranial magnetic stimulation or TMS. When pulses of TMS are delivered repetitively, this is called repetitive TMS, or rTMS. These pulses can be delivered at either high (10–20 Hz) or low frequency (less than or equal to 1 Hz) [1]. Most clinical TMS treatments delivered for treating depression are typically given at 10 Hz to 18 Hz [2,3]. The peak magnetic field strength achieved with each pulse is approximately 1.5 Tesla, right underneath the coil, similar in strength to the magnetic field produced by a typical magnetic resonance imaging (MRI) device [4,5].

Related Posts

rTMS depression
March 13, 2024
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)
September 14, 2023
Effect of high frequency versus theta-burst repetitive transcranial magnetic stimulation on suicidality in patients with treatment-resistant depression
September 8, 2023
Effect of repetitive transcranial magnetic stimulation on anxiety symptoms in patients with major depression: An analysis from the THREE‐D trial
September 8, 2023
Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after 2 antidepressant treatment failures
September 8, 2023
rTMS and application for OCD
February 15, 2019
The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy
February 15, 2019
RANZCP Clinical Practice Guidelines for Mood Disorders
February 15, 2019
Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression
February 15, 2019
Repetitive transcranial magnetic stimulation in the treatment of depression
February 15, 2019
TMS Australia. A safety guide for psychiatrists.
May 7, 2018
A multisite, naturalistic, observational study of TMS for patients with pharmacoresistant major depressive disorder – 2014
March 14, 2015
The expanding evidence base for rTMS treatment of depression – 2014
March 6, 2015
TMS for treating depression in elderly patients – 2013
March 6, 2015
Daily Left Prefrontal rTMS in the acute treatment of major depression – 2008
March 6, 2015
Should we expand the toolbox of psychiatric methods to include rTMS? – 2010
March 6, 2015
Efficacy and Safety of TMS in the Acute Treatment of Major Depression – 2007
March 6, 2015
Comparing the Effects of rTMS and ECT in the Treatment of Depression – 2014
March 3, 2015
TMS: Summary of Safety Experience from Acute Exposure – 2008
March 3, 2015
Durability of clinical benefit with TMS – 2010
March 3, 2015